Linked Life Data

17363532

Source:http://linkedlifedata.com/resource/pubmed/id/17363532

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2007-3-16
pubmed:abstractText
To define the maximum tolerated dose (MTD), toxicities, and pharmacokinetics of 17-allylamino-17-demethoxygeldanamycin (17-AAG) when administered using continuous and intermittent dosing schedules.
pubmed:grant
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1078-0432
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
13
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1775-82
pubmed:dateRevised
2011-10-28
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
pubmed:affiliation
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Phase I, Research Support, N.I.H., Extramural